• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

CYCLOBENZAPRINE Drug Record

  • Summary
  • Interactions
  • Claims
  • CYCLOBENZAPRINE chembl:CHEMBL669 Approved

    Alternate Names:

    CYCLOBENZAPRINE
    MK-130 (AS THE BASE)
    TNX-102
    FLEXERIL
    CICLOBENZAPRINA
    N,N-DIMETHYL-5H-DIBENZO(A,D)CYCLOHEPTENE-DELTA(5,GAMMA)-PROPYLAMINE
    N,N-DIMETHYL-5H-DIBENZO(A,D)CYCLOHEPTENE-Δ5,Γ-PROPYLAMINE
    FEXMID
    MK-130
    (3-DIBENZO[A,D]CYCLOHEPTEN-5-YLIDENE-PROPYL)-DIMETHYL-AMINE
    CYCLOBENZAPRINUM
    AMRIX®
    chembl:CHEMBL669
    rxcui:21949
    pubchem.compound:2895
    drugbank:00924
    chemidplus:303-53-7

    Drug Info:

    Drug Categories antidepressive agents, tricyclic
    FDA Approval 1977
    Drug Class small molecule
    Drug Indications Antidepressive Agents, Tricyclic
    Drug Class antidepressive agents, tricyclic
    Year of Approval 1977
    Drug Categories agents that reduce seizure threshold
    Drug Categories centrally-mediated muscle relaxation
    Drug Categories cytochrome p-450 cyp3a substrates
    Drug Categories cytochrome p-450 substrates
    Drug Categories drugs causing inadvertant photosensitivity
    Drug Categories neurotoxic agents
    Drug Categories photosensitizing agents
    Drug Categories serotonergic drugs shown to increase risk of serotonin syndrome
    Drug Categories ugt1a4 substrates
    (4 More Sources)

    Publications:

    Kobayashi et al., 1996, Cyclobenzaprine, a centrally acting muscle relaxant, acts on descending serotonergic systems., Eur. J. Pharmacol.
    Mestres J et al., 2011, Linking pharmacology to clinical reports: cyclobenzaprine and its possible association with serotonin syndrome., Clin Pharmacol Ther
    Honda et al., 2003, Tricyclic analogs cyclobenzaprine, amitriptyline and cyproheptadine inhibit the spinal reflex transmission through 5-HT(2) receptors., Eur. J. Pharmacol.
    Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
    Obach RS et al., 2004, Human liver aldehyde oxidase: inhibition by 239 drugs., J Clin Pharmacol
    Hutchinson MR et al., 2010, Evidence that tricyclic small molecules may possess toll-like receptor and myeloid differentiation protein 2 activity., Neuroscience
  • CYCLOBENZAPRINE   AOX1

    Interaction Score: 1.25

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    14681337


    Sources:
    DrugBank

  • CYCLOBENZAPRINE   TLR4

    Interaction Score: 0.69

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    21975349 20381591


    Sources:
    DrugBank

  • CYCLOBENZAPRINE   HTR6

    Interaction Score: 0.17

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    21975349


    Sources:
    DrugBank

  • CYCLOBENZAPRINE   HTR2A

    Interaction Score: 0.16

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    8884233 21975349 12498911


    Sources:
    TEND TdgClinicalTrial TTD DrugBank

  • CYCLOBENZAPRINE   HTR7

    Interaction Score: 0.13

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    21975349


    Sources:
    DrugBank

  • CYCLOBENZAPRINE   SLC6A2

    Interaction Score: 0.11

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    21975349


    Sources:
    DrugBank

  • CYCLOBENZAPRINE   HTR2B

    Interaction Score: 0.11

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    21975349


    Sources:
    DrugBank

  • CYCLOBENZAPRINE   SLC6A4

    Interaction Score: 0.1

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    21975349


    Sources:
    DrugBank

  • CYCLOBENZAPRINE   CYP3A5

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • CYCLOBENZAPRINE   HTR2C

    Interaction Score: 0.07

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    21975349


    Sources:
    DrugBank

  • CYCLOBENZAPRINE   ADRA2C

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • CYCLOBENZAPRINE   DRD1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CYCLOBENZAPRINE   CYP2D6

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DrugBank: DB00924

    • Version: 5.1.7

    Alternate Names:
    CYCLOBENZAPRINE DrugBank Drug Name
    303-53-7 CAS Number
    Ag-cyclobenzaprine Drug Brand

    Drug Info:
    Drug Type small molecule
    Drug Groups approved
    Drug Categories agents that reduce seizure threshold

    Publications:
    Mestres J et al., 2011, Linking pharmacology to clinical reports: cyclobenzaprine and its possible association with serotonin syndrome., Clin Pharmacol Ther
    Kobayashi et al., 1996, Cyclobenzaprine, a centrally acting muscle relaxant, acts on descending serotonergic systems., Eur. J. Pharmacol.
    Honda et al., 2003, Tricyclic analogs cyclobenzaprine, amitriptyline and cyproheptadine inhibit the spinal reflex transmission through 5-HT(2) receptors., Eur. J. Pharmacol.

  • TEND: CYCLOBENZAPRINE

    • Version: 01-August-2011

    Alternate Names:
    CYCLOBENZAPRINE Primary Drug Name

    Drug Info:
    Year of Approval 1977
    Drug Class antidepressive agents, tricyclic

    Publications:

  • TdgClinicalTrial: CYCLOBENZAPRINE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications Antidepressive Agents, Tricyclic
    Drug Class small molecule
    FDA Approval 1977

    Publications:

  • PharmGKB: cyclobenzaprine

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem

  • DTC: CYCLOBENZAPRINE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL669 ChEMBL Drug ID

    Drug Info:

    Publications:

  • TTD: Cyclobenzaprine

    • Version: 2020.06.01

    Alternate Names:
    D01KHH TTD Drug ID

    Drug Info:

    Publications:

  • TTD: TNX-102

    • Version: 2020.06.01

    Alternate Names:
    D0NN8N TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL669

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21